Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02807051 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects
A Phase 1 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02807051: Completed Phase 1 study, sponsored by CTI BioPharma.
NCT02807051 is a Phase 1 study that has completed, run by CTI BioPharma. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02807051, a Phase 1 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This will be an open-label, single-center, crossover, one-way, drug-interaction study to evaluate the effect of 500 mg clarithromycin BID (dosed to steady state) on the PK of a single 400-mg dose of pacritinib in healthy male and female subjects.
Interventions
- DRUG Pacritinib
- DRUG Clarithromycin
- DRUG Pacritinib and Clarithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-09 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02807051
The ClinicalTrials.gov registry entry for NCT02807051 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pacritinib is the first listed.
NCT02807051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02807051 about?
NCT02807051 is a clinical study titled "To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects". This will be an open-label, single-center, crossover, one-way, drug-interaction study to evaluate the effect of 500 mg clarithromycin BID (dosed to steady state) on the PK of a single 400-mg dose of pacritinib in healthy male and female subjects.
What is the current status of trial NCT02807051?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-09. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02807051?
The interventions under investigation include: Pacritinib (DRUG), Clarithromycin (DRUG), Pacritinib and Clarithromycin (DRUG).
Who is sponsoring clinical trial NCT02807051?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.